Effect of Transdermal Estradiol and Insulin-like Growth Factor-1 on Bone Endpoints of Young Women With Anorexia Nervosa.
Administration, Cutaneous
Adolescent
Anorexia Nervosa
/ blood
Biomarkers
/ blood
Bone Density
/ drug effects
Bone Remodeling
/ drug effects
Double-Blind Method
Drug Therapy, Combination
Estradiol
/ administration & dosage
Estrogen Replacement Therapy
/ methods
Estrogens
/ administration & dosage
Female
Humans
Insulin-Like Growth Factor I
/ administration & dosage
Longitudinal Studies
Treatment Outcome
Young Adult
IGF-1
adolescents
anorexia nervosa
bone density
bone microarchitecture
estradiol
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
16 06 2021
16 06 2021
Historique:
received:
11
09
2020
pubmed:
12
3
2021
medline:
5
10
2021
entrez:
11
3
2021
Statut:
ppublish
Résumé
Anorexia nervosa (AN) is prevalent in adolescent girls and is associated with bone impairment driven by hormonal alterations in nutritional deficiency. To assess the impact of estrogen replacement with and without recombinant human insulin-like growth factor-1 (rhIGF-1) administration on bone outcomes. Double-blind, randomized, placebo-controlled 12-month longitudinal study. Seventy-five adolescent and young adult women with AN age 14 to 22 years. Thirty-three participants completed the study. Transdermal 17-beta estradiol 0.1 mg/day with (i) 30 mcg/kg/dose of rhIGF-1 administered subcutaneously twice daily (AN-IGF-1+) or (ii) placebo (AN-IGF-1-). The dose of rhIGF-1 was adjusted to maintain levels in the upper half of the normal pubertal range. Bone turnover markers and bone density, geometry, microarchitecture, and strength estimates. Over 12 months, lumbar areal bone mineral density increased in AN-IGF-1- compared to AN-IGF-1+ (P = 0.004). AN-IGF-1+ demonstrated no improvement in areal BMD in the setting of variable compliance to estrogen treatment. Groups did not differ for 12-month changes in bone geometry, microarchitecture, volumetric bone mineral density (vBMD), or strength (and results did not change after controlling for weight changes over 12 months). Both groups had increases in radial cortical area and vBMD, and tibia cortical vBMD over 12 months. Levels of a bone resorption marker decreased in AN-IGF-1- (P = 0.042), while parathyroid hormone increased in AN-IGF-1+ (P = 0.019). AN-IGF-1- experienced irregular menses more frequently than did AN-IGF-1+, but incidence of all other adverse events did not differ between groups. We found no additive benefit of rhIGF-1 administration for 12 months over transdermal estrogen replacement alone in this cohort of young women with AN.
Identifiants
pubmed: 33693703
pii: 6161507
doi: 10.1210/clinem/dgab145
pmc: PMC8427708
doi:
Substances chimiques
Biomarkers
0
Estrogens
0
Estradiol
4TI98Z838E
Insulin-Like Growth Factor I
67763-96-6
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2021-2035Subventions
Organisme : NICHD NIH HHS
ID : T32 HD007184
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK062249
Pays : United States
Organisme : NIDDK NIH HHS
ID : K23 DK115903
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK040561
Pays : United States
Organisme : NHLBI NIH HHS
ID : K24 HL092902
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Trends Endocrinol Metab. 2012 Nov;23(11):576-81
pubmed: 22595550
J Bone Miner Res. 2014 Jan;29(1):151-7
pubmed: 23744513
Einstein (Sao Paulo). 2014 Apr;12(2):175-80
pubmed: 25003922
Diabetes Care. 1990 Apr;13(4):401-11
pubmed: 2318100
J Clin Endocrinol Metab. 2002 Jun;87(6):2883-91
pubmed: 12050268
J Clin Endocrinol Metab. 2014 Apr;99(4):1322-9
pubmed: 24456286
J Pediatr. 1952 Apr;40(4):423-41
pubmed: 14918032
Arch Gen Psychiatry. 2002 Jun;59(6):545-52
pubmed: 12044197
J Clin Endocrinol Metab. 2008 Apr;93(4):1231-7
pubmed: 18089702
J Clin Endocrinol Metab. 2008 Apr;93(4):1292-7
pubmed: 18089697
J Clin Endocrinol Metab. 2007 Jun;92(6):2046-52
pubmed: 17356044
J Clin Endocrinol Metab. 2005 Jun;90(6):3179-85
pubmed: 15784715
J Bone Miner Res. 1995 May;10(5):711-5
pubmed: 7639106
J Clin Endocrinol Metab. 2021 Jun 16;106(7):2021-2035
pubmed: 33693703
J Bone Miner Res. 2020 Feb;35(2):248-260
pubmed: 31603998
Endocrinology. 2002 Feb;143(2):627-35
pubmed: 11796519
J Clin Endocrinol Metab. 1999 Dec;84(12):4489-96
pubmed: 10599707
J Pediatr Adolesc Gynecol. 2002 Jun;15(3):135-43
pubmed: 12106749
J Adolesc Health. 2019 Mar;64(3):305-310
pubmed: 30819332
J Clin Endocrinol Metab. 1989 Mar;68(3):548-54
pubmed: 2493036
J Clin Endocrinol Metab. 2012 Jun;97(6):2124-33
pubmed: 22496496
J Clin Endocrinol Metab. 2013 May;98(5):1923-9
pubmed: 23509107
Endocrinology. 1990 Oct;127(4):1804-10
pubmed: 2401235
Br J Sports Med. 2019 Feb;53(4):229-236
pubmed: 30301734
Arch Gen Psychiatry. 2011 Jul;68(7):714-23
pubmed: 21383252
J Adolesc Health. 2019 Oct;65(4):462-468
pubmed: 31227390
Osteoporos Int. 2017 Apr;28(4):1255-1263
pubmed: 27909781
J Clin Endocrinol Metab. 2002 Sep;87(9):4177-85
pubmed: 12213868
Bone. 2018 Jan;106:61-68
pubmed: 28694162
J Bone Miner Res. 2011 Oct;26(10):2430-8
pubmed: 21698665
J Clin Endocrinol Metab. 2002 Nov;87(11):4935-41
pubmed: 12414853
J Clin Endocrinol Metab. 2003 Dec;88(12):5615-23
pubmed: 14671143
Pediatrics. 2002 Jan;109(1):45-60
pubmed: 11773541
J Clin Endocrinol Metab. 2019 May 1;104(5):1449-1458
pubmed: 30476179
J Clin Endocrinol Metab. 2007 Jun;92(6):2087-99
pubmed: 17311856
J Clin Endocrinol Metab. 2004 Oct;89(10):4972-80
pubmed: 15472193
Bone. 2009 Sep;45(3):493-8
pubmed: 19523548
J Adolesc Health. 2017 Feb;60(2):229-232
pubmed: 27939877